- Investing Ideas
- U.S. Biotech Breakthroughs
U.S. Biotech Breakthroughs
Results
54
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
54 companies
Arcutis Biotherapeutics
Market Cap: US$3.2b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$27.32
7D
7.7%
1Y
135.3%
Ardelyx
Market Cap: US$1.7b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$7.32
7D
-4.8%
1Y
31.2%
Marker Therapeutics
Market Cap: US$27.7m
A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
MRKR
US$1.65
7D
3.1%
1Y
-6.8%
Legend Biotech
Market Cap: US$3.1b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$17.10
7D
-2.3%
1Y
-51.7%
Lineage Cell Therapeutics
Market Cap: US$407.1m
A clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally.
LCTX
US$1.70
7D
14.9%
1Y
153.7%
Madrigal Pharmaceuticals
Market Cap: US$10.5b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$477.60
7D
-2.4%
1Y
43.5%
Achieve Life Sciences
Market Cap: US$210.3m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$4.25
7D
1.7%
1Y
39.3%
Aldeyra Therapeutics
Market Cap: US$306.2m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$5.53
7D
3.2%
1Y
-6.7%
Pelthos Therapeutics
Market Cap: US$72.0m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$22.99
7D
-4.3%
1Y
79.6%
RenovoRx
Market Cap: US$34.9m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$0.99
7D
-4.8%
1Y
-14.7%
ARS Pharmaceuticals
Market Cap: US$955.9m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$10.03
7D
0.4%
1Y
-15.9%
Soleno Therapeutics
Market Cap: US$2.1b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$41.53
7D
7.7%
1Y
-17.6%
Capricor Therapeutics
Market Cap: US$1.2b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$24.72
7D
12.9%
1Y
75.4%
Citius Oncology
Market Cap: US$98.0m
Focuses on the development and commercialization of innovative targeted oncology therapies.
CTOR
US$1.13
7D
6.6%
1Y
-4.2%
Longeveron
Market Cap: US$10.9m
A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
LGVN
US$0.51
7D
-8.3%
1Y
-66.3%
AC Immune
Market Cap: US$292.9m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$3.14
7D
-1.6%
1Y
16.7%
Syndax Pharmaceuticals
Market Cap: US$1.8b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$21.01
7D
3.4%
1Y
35.4%
Viridian Therapeutics
Market Cap: US$2.8b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$29.25
7D
-11.4%
1Y
64.7%
Caris Life Sciences
Market Cap: US$6.0b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$22.00
7D
-5.0%
1Y
n/a
Precigen
Market Cap: US$1.5b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$4.29
7D
-4.5%
1Y
152.4%
Insmed
Market Cap: US$32.2b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$149.86
7D
-4.5%
1Y
87.4%
Vera Therapeutics
Market Cap: US$2.9b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases.
VERA
US$43.50
7D
0.6%
1Y
20.4%
Altimmune
Market Cap: US$616.1m
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
ALT
US$4.87
7D
-13.0%
1Y
-26.9%
Ocugen
Market Cap: US$436.1m
A biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health.
OCGN
US$1.33
7D
-8.3%
1Y
86.7%
Rhythm Pharmaceuticals
Market Cap: US$6.9b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
RYTM
US$103.61
7D
1.1%
1Y
75.1%
Unicycive Therapeutics
Market Cap: US$133.0m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$6.69
7D
12.1%
1Y
18.3%
Praxis Precision Medicines
Market Cap: US$8.5b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance.
PRAX
US$319.57
7D
1.8%
1Y
267.8%
BioRestorative Therapies
Market Cap: US$9.1m
Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
BRTX
US$1.04
7D
-8.8%
1Y
-54.8%
Roivant Sciences
Market Cap: US$18.5b
A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
ROIV
US$25.82
7D
19.4%
1Y
137.1%
Savara
Market Cap: US$1.3b
A clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
SVRA
US$5.30
7D
-1.9%
1Y
91.3%
Day One Biopharmaceuticals
Market Cap: US$1.1b
A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
DAWN
US$11.41
7D
2.2%
1Y
-5.3%
Cogent Biosciences
Market Cap: US$5.4b
A biotechnology company, focuses on developing precision therapies for genetically defined diseases.
COGT
US$37.08
7D
3.3%
1Y
324.3%
Zymeworks
Market Cap: US$1.6b
A clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID).
ZYME
US$22.72
7D
0.8%
1Y
59.1%
Amicus Therapeutics
Market Cap: US$4.5b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$14.30
7D
0.07%
1Y
48.2%
Prelude Therapeutics
Market Cap: US$166.4m
A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
PRLD
US$2.17
7D
17.3%
1Y
114.9%
Creative Medical Technology Holdings
Market Cap: US$6.2m
A commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
CELZ
US$1.93
7D
-4.5%
1Y
-54.4%